- Home
- / Sunzen Biotech
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Sunzen Biotech financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
RM80.6 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| MYR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 300.4M | 243.7M | 82.2M | 90.5M | 97.1M | 142.7M | 80.6M |
| Cost of goods sold | 277.1M | 222.4M | 71.5M | 72.0M | 70.4M | 100.8M | 53.3M |
| Gross profit | 29.3M | 22.1M | 11.9M | 21.1M | 29.0M | 44.5M | 28.1M |
| Gross profit margin, % | 9.1% | 14.4% | 23.3% | 29.9% | 31.2% | 34.9% | |
| Operating expense total | 26.2M | 27.7M | 25.1M | 16.8M | 18.8M | 25.0M | 21.7M |
| Depreciation and amortization | 10.6M | 8.3M | 2.8M | 2.6M | 2.8M | 3.5M | 2.3M |
| EBITDA | 3.1M | (5.6M) | (13.2M) | 4.3M | 10.2M | 19.1M | 5.9M |
| EBITDA margin, % | -2.3% | -16.0% | 4.8% | 10.5% | 13.4% | 7.3% | |
| EBIT | (7.4M) | (17.7M) | (12.8M) | 1.7M | 7.4M | 16.4M | 3.6M |
| EBIT margin, % | -7.3% | -15.6% | 1.9% | 7.6% | 11.5% | 4.4% | |
| Interest income | 585.0K | 490.0K | 89.0K | 45.0K | 36.0K | 64.0K | 66.0K |
| Interest expense | 277.0K | 626.0K | 604.0K | 259.0K | 208.0K | 431.0K | 481.0K |
| Pre tax profit | (6.9M) | (17.9M) | (12.7M) | 3.7M | 7.5M | 15.9M | 3.3M |
| Income tax expense | (3.0K) | 34.0K | 209.0K | 1.8M | 2.7M | 5.3M | 617.0K |
| Net Income | (6.9M) | (18.0M) | (12.9M) | 1.9M | 4.8M | 10.6M | 2.7M |